Andrew KeithMar 26, 2021Diurnal Group - Efmody (Chronocort) recommended for approval in EUThe EMA's recommendation to approve Efmody (formerly known as Chronocort) for the treatment of congenital adrenal hyperplasia (CAH)...
Brian WhiteMar 5, 2021Basilea - Amgen to acquire Five Prime Therapeutics for $1.9bnAmgen's proposed acquisition of Five Prime Therapeutics for $1.9bn in cash, accessing its lead oncology programme bemarituzumab - a...
Andrew KeithMar 3, 2021Diurnal Group - A new dawn Diurnal faces an imminent regulatory decision on Chronocort, it’s most important product to date. Our note published today revisits the...
Andrew KeithFeb 22, 2021Basilea's lisavanbulinBasilea's lisavanbulin is a promising therapy for brain cancer (glioblastoma multiforme), one of the most challenging and difficult to...
Brian WhiteFeb 12, 2021Basilea reports further detail on derazantinib/checkpoint inhibitor combination With the recent publication of the topline results from the monotherapy FIDES-01 study for Basilea's lead oncology candidate derazantinib...